Lower Revenue and Profit in European Operations
First written in FY2017-Q2. 13 of 39 entries say "Worsened", first in FY2019-Q3. Latest entry: 2026-08-07.
Advanex moved to the "Worse" side of this theme in 2024, 4 years after the typical company in this theme (2020).
The whole theme swung hardest in 2025: 9 of 18 companies on the "Worse" side.
5 other companies' latest entry also says "Worsened".
- FY2026Revenue up, but European profit downAnnual report
「Although the start of mass production for the new medical-sector business was delayed, the recovery in sales to the aerospace sector drove revenue up 4.2% year on year to ¥3.543 billion. Segment profit fell 46.6% to ¥80 million as fixed and other costs increased due in part to upfront investment in the medical business at the Czech plant.」
In Europe, revenue increased due to the recovery in sales to the aerospace sector, while fixed costs increased because of upfront investment in the medical business at the Czech plant, causing segment profit to fall 46.6%. - FY2026-H1WorsenedAnnual report
「Revenue fell 8.9% year on year to ¥1.474 billion as sales to the aerospace sector struggled under the impact of US tariffs. Segment results were a loss of ¥153 million, compared with profit of ¥18 million in the previous year, as fixed and other costs increased due in part to higher labor and energy costs.」
In Europe, sales to the aerospace sector struggled due to the impact of US tariffs, resulting in lower revenue. Combined with higher labor and energy costs, this caused the segment to swing from profit in the previous year to a loss of ¥153 million. - FY2025WorsenedAnnual report
「Revenue rose 9.3% year on year to ¥3.399 billion, but segment profit fell 34.7% to ¥150 million as fixed and other costs increased due in part to higher labor and energy costs.」
In Europe, revenue increased, while segment profit fell 34.7% due to higher labor and energy costs. - FY2025-H1WorsenedAnnual report
「Revenue rose 5.4% year on year to ¥1.618 billion, but declined in local-currency terms. In addition, higher labor and energy costs caused segment profit to fall 74.1% to ¥18 million.」
In Europe, revenue increased in yen terms but declined in local-currency terms, while segment profit fell 74.1% year on year due to higher labor and energy costs. - FY2024WorsenedAnnual report
「The recovery in sales to the medical sector and the impact of foreign exchange drove revenue up 5.8% year on year to ¥3.111 billion. Segment profit fell 38.6% to ¥230 million due to higher labor and energy costs.」
In Europe, revenue increased, while segment profit fell 38.6% year on year due to higher labor and energy costs. - FY2024-Q3WorsenedAnnual report
「The recovery in sales to the aerospace and medical sectors and the impact of foreign exchange drove revenue up 18.0% year on year to ¥2.244 billion. Segment profit fell 21.9% to ¥73 million due to higher labor and energy costs.」
In Europe, revenue increased due to the recovery in the aerospace and medical sectors and the impact of foreign exchange, while segment profit fell 21.9% due to higher labor and energy costs. - FY2024-Q2AdvancedAnnual report
「The recovery in sales to the aerospace and medical sectors and the impact of foreign exchange drove revenue up 26.9% year on year to ¥1.535 billion, while segment profit rose 75.1% to ¥70 million despite higher labor and energy costs.」
In Europe, revenue increased due to the recovery in the aerospace and medical sectors and the impact of foreign exchange, while segment profit rose 75.1% despite higher labor and energy costs. - FY2024-Q1AdvancedAnnual report
「The recovery in sales to the aerospace and medical sectors and the impact of foreign exchange drove revenue up 53.3% year on year to ¥755 million. Despite higher labor and energy costs, segment profit was ¥52 million, compared with a loss of ¥17 million in the same quarter of the previous year.」
In Europe, revenue increased due to the recovery in the aerospace and medical sectors and the impact of foreign exchange, while segment profit turned from a loss in the previous year to a profit. - FY2023AdvancedAnnual report
「The recovery in sales to the medical and aerospace sectors, the weaker yen and the effect of price increases drove revenue up 43.6% year on year to ¥2.939 billion. Despite factors weighing on earnings, including higher material and energy costs, segment profit rose 613.3% to ¥375 million, helped substantially by the effect of price increases.」
In Europe, revenue and profit increased substantially due to the recovery in the medical and aerospace sectors, the weaker yen and the effect of price increases. Higher costs remained an issue, but price pass-through contributed to improved profit. - FY2023-Q3AdvancedAnnual report
「The recovery in sales to the medical and aerospace sectors, along with the impact of the weaker yen, drove revenue up 26.6% year on year to ¥1.902 billion. Despite factors weighing on earnings, including higher material and energy costs, segment profit rose 179.5% to ¥94 million as price pass-through advanced.」
In Europe, revenue increased due to the recovery in the medical and aerospace sectors and the weaker yen, while segment profit rose 179.5% year on year as price pass-through advanced. - FY2023-Q2Higher Revenue but Lower ProfitAnnual report
「The recovery in sales to the medical and aerospace sectors, along with the impact of the weaker yen, drove revenue up 17.7% year on year to ¥1.210 billion. Segment profit fell 25.6% to ¥40 million due to higher material and energy costs.」
In Europe, revenue increased due to the recovery in the medical and aerospace sectors and the weaker yen, while segment profit declined year on year due to higher material and energy costs. - FY2023-Q1WorsenedAnnual report
「Due in part to sluggish sales to the aerospace sector, revenue fell 8.0% year on year to ¥492 million. The segment reported a loss of ¥17 million, compared with profit of ¥67 million in the same quarter of the previous year, due to higher raw material and energy costs.」
In Europe, revenue declined because of sluggish sales to the aerospace sector, and higher raw material and energy costs caused the segment to swing from profit in the previous year to a loss. - FY2022WorsenedAnnual report
「(Europe) Strong sales to the automotive and medical sectors drove revenue up 5.7% year on year to ¥2.046 billion, but segment profit fell 70.6% to ¥52 million due to an unfavorable product mix, including lower sales to the aerospace sector.」
In Europe, revenue increased, while segment profit fell 70.6% year on year due to an unfavorable product mix, including lower sales to the aerospace sector. - FY2022-Q3WorsenedAnnual report
「Revenue increased by 8.9% year on year to ¥1.503 billion due to strong automotive and medical-related demand, but segment profit decreased by 63.4% to ¥33 million due to a deterioration in the product mix, including a decline in aircraft-related demand.」
In Europe, revenue increased on strong automotive and medical-related demand, while segment profit decreased by 63.4% year on year due to a deterioration in the product mix, including a decline in aircraft-related demand. - FY2022-Q2Higher Revenue but Lower ProfitAnnual report
「Revenue increased by 10.6% year on year to ¥1.028 billion due to strong medical-related demand and standard products, but segment profit decreased by 22.0% to ¥54 million.」
In Europe, revenue increased on strong medical-related demand and standard products, while segment profit decreased by 22.0% year on year. - FY2022-Q1AdvancedAnnual report
「Revenue increased by 12.7% year on year to ¥535 million, and segment profit increased by 18.7% to ¥67 million, due to strong medical-related demand and standard products.」
In Europe, revenue and profit increased on strong medical-related demand and standard products. - FY2021WorsenedAnnual report
「Revenue decreased by 12.1% year on year to ¥1.936 billion due to a decline in demand for standard products, among other factors. Segment profit decreased by 26.1% to ¥179 million due to higher maintenance costs at the Czech plant, among other factors.」
In Europe, revenue declined due to lower demand for standard products, while profit also decreased by 26.1% year on year due to maintenance costs at the Czech plant and other factors. - FY2021-Q3Revenue down, but profit up through rationalisationAnnual report
「Revenue decreased by 11.8% year on year to ¥1.380 billion due to a decline in demand for standard products, among other factors. Although costs increased due to delays in the start of mass production at the Czech plant caused by the COVID-19 pandemic, segment profit increased by 79.2% to ¥92 million, reflecting the rationalisation of the production structure in the UK, among other factors.」
In Europe, revenue declined due to lower demand for standard products and delays in the start of mass production at the Czech plant, while segment profit increased by 79.2% year on year due to the rationalisation of the production structure in the UK. - FY2021-Q2AdvancedAnnual report
「Revenue decreased by 8.3% year on year to ¥930 million due to a decline in demand for standard products, among other factors. Segment profit increased by 45.5% to ¥69 million, reflecting the rationalisation of the production structure in the UK, among other factors.」
In Europe, revenue declined due to lower demand for standard products, while segment profit increased by 45.5% year on year due to the rationalisation of the production structure in the UK. - FY2021-Q1Revenue down, but profit up sharplyAnnual report
「Revenue decreased by 10.4% year on year to ¥475 million due to a decline in demand for standard products, among other factors. Segment profit increased by 396.0% to ¥57 million, as relatively profitable products, including medical-related products, remained comparatively firm.」
In the European business, revenue declined due to lower demand for standard products, while segment profit increased by 396.0% year on year as profitable medical-related products remained firm. - FY2020AdvancedAnnual report
「Revenue increased by 8.9% year on year to ¥2.202 billion on strong aircraft-related demand, among other factors. Segment profit increased by 29.6% to ¥242 million, despite higher startup costs at the Czech plant, partly due to an improved product mix.」
Despite ongoing startup costs at the Czech plant, revenue and profit in Europe increased on strong aircraft-related demand and an improved product mix. - FY2020-Q3WorsenedAnnual report
「Revenue increased by 4.4% year on year to ¥1.565 billion on strong aircraft-related demand, among other factors. Segment profit decreased by 42.0% to ¥51 million due to higher startup costs at the Czech plant, among other factors.」
In Europe, revenue increased on strong aircraft-related demand, while segment profit decreased by 42.0% year on year due to startup costs at the Czech plant. The deterioration in profitability widened from the previous quarter's 38.3% rate of decline. - FY2020-Q2MitigatedAnnual report
「Although aircraft-related demand remained strong, revenue decreased by 0.7% year on year to ¥1.013 billion, partly due to foreign exchange effects. Segment profit decreased by 38.3% to ¥47 million due to higher startup costs at the Czech plant, among other factors.」
Profit continued to decline due to startup costs at the Czech plant, but the year-on-year rate of decline in segment profit narrowed from 79.6% in the previous quarter to 38.3%. - FY2020-Q1WorsenedAnnual report
「Although aircraft-related demand remained strong, revenue decreased by 0.9% year on year to ¥530 million, partly due to foreign exchange effects. Segment profit decreased by 79.6% to ¥11 million due to higher startup costs at the Czech plant, among other factors.」
In Europe, aircraft-related demand was strong, but revenue declined, and segment profit fell sharply by 79.6% year on year due to startup costs at the Czech plant and other factors. - FY2019-Q3WorsenedAnnual report
「Revenue increased by 9.4% year on year to ¥1.498 billion on strong automotive and aircraft-related demand, among other factors, but segment profit decreased by 46.8% to ¥89 million due to costs incurred in preparing to open the new Czech plant, among other factors.」
Revenue in Europe increased, while segment profit decreased due to costs of preparing to open the new Czech plant and other factors. The year-on-year rate of decline in profit widened from the previous quarter. - FY2019-Q2Higher Revenue but Lower ProfitAnnual report
「Revenue increased by 16.5% year on year to ¥1.021 billion on strong automotive and aircraft-related demand, among other factors, but segment profit decreased by 19.8% to ¥77 million due to costs incurred in preparing to open a new plant in the Czech Republic and rising material costs, among other factors.」
In Europe, revenue increased on strong automotive and aircraft-related demand, while segment profit decreased due to costs of preparing to open the new Czech plant and rising material costs. - FY2019-Q1AdvancedAnnual report
「Revenue increased by 24.6% year on year to ¥535 million and segment profit increased by 87.9% to ¥56 million, reflecting strong medical- and aircraft-related demand, among other factors.」
In Europe, revenue and segment profit both increased year on year on strong medical- and aircraft-related demand. - FY2018Higher Revenue but Lower ProfitAnnual report
「Revenue increased by 8.5% year on year to ¥1.871 billion due to strong medical-related demand, but segment profit decreased by 4.1% to ¥238 million due to a change in the allocation of head office expenses, among other factors.」
In Europe, revenue increased on strong medical-related demand, while segment profit decreased due to a change in the allocation of head office expenses. - FY2018-Q3AdvancedAnnual report
「Revenue increased by 8.7% year on year to ¥1.369 billion and segment profit increased by 25.1% to ¥167 million, due to strong medical-related demand and successful initiatives to reduce fixed costs, among other factors.」
In Europe, both revenue and segment profit increased year on year on strong medical-related demand and initiatives to reduce fixed costs. Profit improvement continued from the first and second quarters. - FY2018-Q2AdvancedAnnual report
「Revenue increased by 0.1% year on year to ¥876 million and segment profit increased by 37.5% to ¥96 million, due to strong medical-related demand and the success of initiatives to reduce fixed costs, among other factors.」
Revenue in Europe was essentially flat year on year, while segment profit increased by 37.5% on strong medical-related demand and initiatives to reduce fixed costs. Specific drivers of improvement emerged following the increase in profit in the first quarter. - FY2018-Q1MitigatedAnnual report
「Revenue decreased by 4.5% year on year to ¥429 million due to the weaker pound and other factors, but segment profit increased by 16.4% to ¥30 million, reflecting strong medical-related demand, among other factors.」
In Europe, revenue declined due to the weaker pound, but segment profit increased year on year on the strength of medical-related demand, improving profitability after previous declines in both revenue and profit. - FY2017MitigatedAnnual report
「Due to the stronger yen and a decline in medical-related demand, among other factors, revenue decreased by 24.6% year on year to ¥1.725 billion and segment profit decreased by 29.1% to ¥248 million.」
The decline in revenue and profit in the European business continued for the full fiscal year, but the rates of decline in revenue and segment profit narrowed from the cumulative third-quarter levels. - FY2017-Q3MitigatedAnnual report
「Although aircraft-related demand remained strong, revenue decreased by 28.3% year on year to ¥1.260 billion and segment profit decreased by 39.2% to ¥133 million, due in part to the stronger yen.」
The decline in revenue and profit in the European business continued, but the year-on-year rates of decline narrowed from the second quarter's 29.9% decline in revenue and 52.6% decline in segment profit. - FY2017-Q2First statedAnnual report
「Although aircraft-related demand remained strong, revenue decreased by 29.9% year on year to ¥875 million and segment profit decreased by 52.6% to ¥70 million, due to the stronger yen and a decline in medical-related demand, among other factors.」
In the European segment, aircraft-related demand was strong, but revenue and segment profit decreased year on year due to the stronger yen and a decline in medical-related demand.